Sat0384 comparative Analysis of Frequency and Timing of Minimal Disease Activity (Mda) Attainment in Early and Long-Term Psoriatic Arthritis (Psa) Patients (Pts) After Biological (B) Dmards Treatment Initiation in Clinical Practice: Russian Psa Registry (Ru-Psart) Data

Abstract

BackgroundMDA is a treatment target of PsA. There is limited data about the frequency and the time of MDA achievement by the use of bDMARD therapy in early and long-term PsA in clinical practice. RU-PsART collected data from 25 rheumatology clinics in the Russian Federation.Objectives: to investigate the cumulative frequency and timing of MDA attainment in early and long-term PsA after starting bDMARDs in clinical practice.Methods140 (M/F–77/63) bDMARD-naive PsA pts according to CASPAR criteria were included in the RU-PsART, after signing consent participation forms; median (Me) age 42 [Min 19-Max 73] years (yrs). All patients were divided into two groups based on PsA duration at the time of bDMARDs initiation: early PsA≤2 yrs (67pts) and long-term PsA>2 yrs (73pts). All pts underwent standard clinical examinations of PsA and psoriasis activity and were treated with the following bDMARDs: Infliximab (26pts), Etanercept (20pts), Adalimumab (37pts), Ustekinumab (33pts), Golimumab (19pts), Sekukinumab (4pts), Certolizumab pegol (1pts). MDA was defined as ≥ 5 of the following criteria: tender joint count ≤1, swollen joint count ≤1, PASI≤1 or BSA≤3, patient pain global assessment VAS≤15, patient’s global disease activity VAS≤20, HAQ≤0,5, enthesitis count ≤1. The cumulative frequency and the time of MDA attainment were calculated in both groups. Kaplan-Meier cumulative analysis, Me (CI95%), Min-Max,%, Breslow, Tarone-Ware, Log Rank tests were performed. All CI>1, p<0.05, were considered to indicate statistical significance.ResultsMDA has been achieved after bDMARDs initiation in 33 out of 67 (49%) pts with early PsA and in 23 out of 73 (32%) pts with long-term PsA. The Me time of MDA achievement was significantly shorter in early PsA in comparison to long-term PsA pts: 21 (CI 95%:13.1-28.9) months and 58 (CI95%:0-118.1) months of bDMARD therapy accordingly (p<0.05 for all tests) (Fig.1).Figure 1Cumulative frequency and time of MDA achievement after starting bDMARDs in early and long-term PsA.ConclusionComparative analysis has shown that cumulative frequency of MDA achievement after bDMARDs initiation was significantly higher (49% vs 32%) and faster (21 vs 58 months) in early PsA than in long-term PsA. That confirms the benefit of bDMARD therapy initiation at the early stage of PsA.Disclosure of InterestsElena Loginova Speakers bureau: Novartis, Celgene Corporation, Biocad, Janssen, AbbVie Inc, Tatiana Korotaeva Speakers bureau: Novartis, Celgene Corporation, AbbVie Inc, Biocad, Janssen, Pfizer, UCB, Lilly, Anastasia Koltakova: None declared, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Celgene Corporation, Janssen, Maria Sedunova: None declared, Igor Pristavsky: None declared, Irina Umnova: None declared, Irina Bondareva: None declared, Snezana Kudishina: None declared, Evgeny Nasonov Speakers bureau: Pfizer, Inc., MSD, Novartis, AbbVie Inc., Celgen Corporation, Biocad, Janssen, UCB, Inc.

Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion

“…При анализе данных регистра PSOLAR (Psoriasis Longitudinal Assessment and Registry) более ранний возраст дебюта заболевания (пациенты ≤40 лет) ассоциировался с более выраженным положительным ответом на терапию ГИБП [99]. Применение ГИБП и лечение ПсА на ранней стадии повышают шансы достичь ремиссии заболевания [100,101].…”

Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

“…При анализе данных регистра PSOLAR (Psoriasis Longitudinal Assessment and Registry) более ранний возраст дебюта заболевания (пациенты ≤ 40 лет) ассоциировался с более выраженным положительным ответом на терапию ГИБП [52]. Применение ГИБП и лечение ПсА на ранней стадии повышают шансы достичь ремиссии заболевания [98,99].…”